[How far has non-invasive testing become a surrogate endpoint for the research and development of new drugs for metabolic dysfunction-associated steatohepatitis?].

The research and development of new drugs for metabolic dysfunction-associated steatohepatitis still leads to a high screening failure rate and low efficiency with the repeated liver biopsy as the primary endpoint. Currently, non-invasive testing has been widely used in early-stage efficacy evaluation and patient screening, and evidence of association with clinical outcomes has gradually been established, and a number of new non-invasive scoring systems are also emerging. With the accumulation of data and the improvement of standards, the research and development of new drugs for metabolic dysfunction-associated steatohepatitis is gradually moving from the "histological era" to the "non-invasive era," which is expected to profoundly change clinical trials and disease management strategies.